Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $46

Wells Fargo analyst Benjamin Burnett maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $45 to $46.